by Natasha Davie | Mar 5, 2013
When it comes to the cell therapy commercialization crunch there are some fundamental questions that need to be answered. Is your product going to be frozen or fresh? How will the product be administered? What is your dosing strategy? And the one that I’m going to...
by David Brindley | Jan 16, 2013
claimtoken-510012802486f [pullquote]The cell therapy industry has an encyclopaedic void. But is this void one that needs addressing?”[/pullquote]This post was initially intended to be a short vignette (not so short, as it turns out) exploring whether or not the...
by Paul Krzyzanowski | Jan 8, 2013
This year, your household will pay $360 for the use of Intellectual Property (IP) held by people and corporations outside of Canada. For a little less than a dollar a day, you’re supporting industries like biotechnology, high-tech electronics, and engineering in other...
by David Brindley | Dec 18, 2012
Some words have the ability to induce instant and unexplained anxiety. In developing industries, such as cell therapy, one such example is regulation – of any sort. Crudely, our negative perception of regulation can be attributed to two factors: an aversion to both...
by Michael May | Nov 19, 2012
James Till and Ernest McCulloch identified stem cells 50 years ago in Toronto, and their legacy is a vibrant community of scientists who are leaders in this field of research. But what does that mean in terms of producing products and therapies to heal and cure...
by David Brindley | Nov 5, 2012
Recently, in the twilight on a balmy summer’s evening in DC, an irrationally passionate cell therapy war room convened over meze, ouzo and retsina. And considered the meaty question posed by Lonza’s Jon Rowley: “Where do you think you and the cell therapy industry...
Comments